Sell Sativex; buy cannabis

In Evidence-Based Medicine, Health industry on April 10, 2008 by Alan Lovell Tagged:

An interesting story from yesterday’s FT showing how RCTs can impact on the marketplace and share prices. GW are hurting because an RCT didn’t quite come out as they hoped. Their new (cannabis-based) drug, Sativex, worked! It reduced neuropathic pain. The trouble is, so did placebo…

“GW Pharmaceuticals became the latest casualty in the embattled biotechnology sector on Tuesday, after the pioneer of cannabis-based medicine saw its shares fall by more than a quarter after the failure of a critical clinical trial. The company said a final stage trial for Sativex, its lead drug hope, to treat neuropathic pain in multiple sclerosis patients had shown a high response rate but narrowly failed to show significant benefits because of an unexpectedly large placebo response…”

“The shares fell 19½p to 52p…”


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: